Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a ...
Zacks.com on MSN17h
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage ListEli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.
The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
Christmas has come early for Eli Lilly this year, courtesy of a fresh FDA approval for the Indianapolis drugmaker’s obesity ...
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the first ...
Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback